ABSTRACT Non-specific bronchial reactivity is related to the severity of clinical asthma. Histamine challenge testing is increasingly used in association with questionnaires in epidemiological studies of the prevalence and morbidity of asthma in the community. The histamine challenge method described by Cockcroft et al is widely used and well standardised but it has disadvantages for epidemiological studies, being relatively slow and dependent on a supply of pressurised air. In this study we Since Tiffeneau introduced the concept of an inhalation challenge with histamine as a diagnostic test for asthma in 1958,1 many different methods of testing have been developed. Of these, the method described by Cockcroft et al2 using the Wright nebuliser is particularly well standardised and has been widely adopted in clinical and research work.
Since Tiffeneau introduced the concept of an inhalation challenge with histamine as a diagnostic test for asthma in 1958,1 many different methods of testing have been developed. Of these, the method described by Cockcroft et al2 using the Wright nebuliser is particularly well standardised and has been widely adopted in clinical and research work.
The measurement of non-specific reactivity is of great potential value in the epidemiological investigation of asthma, but in this application the Cockcroft method has certain disadvantages. The test is slow, taking up to 45 minutes to complete, and it is dependent on a supply of pressurised air, making the equipment bulky and relatively expensive.
Recently two alternative methods have been used for epidemiological studies. Yan et al3 have described a method using the hand held DeVilbiss No 40 nebuliser and Mortagy4 a method based on the Pul-masonic ultrasonic nebuliser. Both are completed more quickly than the Cockcroft method, and neither requires an air supply, but their repeatability is less well documented than that of the Cockcroft technique.
In order to select the most suitable method for an epidemiological survey we have compared measurements ofhistamine reactivity using all three methods (Cockcroft, Yan, and Mortagy) in a group of asthmatic subjects, assessing the methods for repeatability and comparability of response.
Methods
Twenty four subjects with asthma were recruited from outpatient clinics and hospital staff in Basingstoke and Southampton. Criteria for inclusion were: age 18-55 years, mild asthma requiring # agonist treatment in the previous 12 months but with stable medication requirements in the last six weeks, and a resting FEV1 above 60% of the predicted value.5
Subjects were excluded if they had had an upper respiratory tract infection in the previous six weeks, or if Histamine challenge testing: comparison of three methods they were taking oral steroids, antihistamines, sodium cromoglycate, ipratropium bromide, or theophylline derivatives, but not if they were taking inhaled steroids (continued as usual throughout the study), or inhaled fi agonists (withheld for six hours before the study). Each subject was tested once with each of the three methods and these were then repeated in the same order, so that there was a total of six tests. The order of tests was determined from a balanced design in which all orders were represented equally.
All 
Cockcroft method2
A Wright nebuliser was driven by air at a flow of 8 1 min-1, which was known from preliminary studies to produce an output of 0.14 ml min-. It was primed with 3 ml solution, and the aerosol was delivered directly to the subject via a face mask without intervening tubing. The subject, wearing a noseclip, inhaled the aerosol by breathing tidally for two minutes with the face mask held loosely over the mouth and nose.
Baseline FEVY and forced vital capacity (FVC)
measurements were recorded until two successive measurements were within 5%. After each inhalation, including that of normal saline, FEV1 was recorded once, unless technically unsatisfactory, at 30 and 90 seconds and at subsequent 90 second intervals until the value was higher than the previous reading. The lowest postinhalation value was taken for analysis. After baseline spirometric measurements the subject inhaled saline, followed by successive inhalations of histamine in doubling concentrations from 0.3 to 8mg/ml.
Yan method3
The output of several DeVilbiss No 40 nebulisers was measured to select five with an output as close as possible to 0.003 ml per puff, and within the authors' specified limits of 0.0018-0.0042 ml. These were primed with 1 ml of either saline or histamine in concentrations of 0.3, 0.6, 2.5, or 5 g/l00ml.
Baseline FEV1 was measured, the greater of two consecutive measurements within 200 ml being taken. Inhalations were administered by expressing one or more puffs from the nebuliser directly in front of the subject's open mouth, at the beginning of a near maximal inspiration from functional residual capacity. The inspiration was held for three seconds.
Three puffs of saline were given in successive inhalations. Measurement of FEV1 was repeated one minute after the last inhalation, and followed immediately by the first inhalation of histamine. Histamine was administered according to the regimen shown in the table, to achieve cumulative doubling doses of 0.03-7.8 pmol.
Mortagy method4
A Pulmasonic ultrasonic nebuliser, primed with 3 ml of solution, generated aerosol continuously. The subject breathed tidally through the nebuliser mouthpiece, and the mouthpiece valve system ensured that aerosol was emitted only during inspiration. Baseline FEV1 and FVC were recorded until three FEV1 values were within 5%. Normal saline was then admininstered for 30 seconds and the FEV1 recorded once after 30 seconds and repeated only if technically unsatisfactory. The nebuliser chamber was then emptied and dried before being primed with the lowest concentration of histamine, which was given 30 seconds later. The procedure was repeated with succesDose regimenfor Yan (fi-AGONIST:OCC), 1 agonist regularly at least once a day (i-AGONIST:REG), and daily , agonist plus beclomethasone (BECLO + P-AGONIST).
sive histamine solutions, in doubling concentrations from 0.3 to 8 mg/ml, at 90 second intervals.
ANALYSIS OF RESULTS
The percentage fall in FEV1 from the postsaline value was plotted against log dose of histamine. The concentration ( The standard deviation of the differences between measurements was used to construct 95% ranges for a single measurement by each method from the formula to.05 (SD)I/V2. Repeatability was compared by the F ratio and by Friedman's test.
Results
Geometric mean PC2o and PD20 values for the three methods for subjects classified according to their regular requirements for inhaled medication are shown in figure 1 . Subjects using no medication were seasonal asthmatics and were symptom free at the time of study.
With the Yan and Mortagy methods PD20 or PC20 values were obtained on both occasions in all 24 subjects. With the Cockcroft method a PC20 of up to 8mg/ml was achieved on both occasions in 16 subjects, on one occasion in four, and on neither occasion in four subjects.
For the subjects in whom two PC20 or PD20 values were obtained mean values with the Cockcroft technique were higher than with the Mortagy method by an average of 2.30 doubling concentrations, and numerically higher (in mg/ml) than PD20 values from the Yan method (in pmol) by a factor of 1.75 doubling increments.
The mean differences (SD in parentheses) between repeat measurements for the Cockcroft, Yan, and Mortagy methods in the 16 subjects in whom both measurements were within the administered dose range were -0.03 (0.49), -0.11 (0.43), and -0.06 (0.40) log1o units (fig2). The differences were normally distributed for the Cockcroft and Yan methods, but not for the Mortagy method. Use of parametric statistical methods, however, did not indicate significant bias between first and second readings with each method (paired t test) or any difference in variance between methods (F ratio). Non-parametric comparison of repeatability (by Friedman's test) also showed no difference between methods. The 95% ranges for a single measurement for the Cockcroft, Yan, and Mortagy methods were + 2.40, 2.11, and 1.94 doubling concentrations or doubling doses.
Discussion
The purpose of this study was to select a challenge method for a large community study of asthma prevalence, for which the Cockcroft method was considered too slow and cumbersome to be practical. We therefore compared the Cockcroft method with two methods that had already been applied successfully in epidemiological work. The main criterion was the repeatability of the three methods we were comparing.
The difference between repeated measurements was normally distributed for the Cockcroft and Yan methods, but non-normal for the Mortagy method. We compared repeatability using the parametric F statistic, as appropriate for the Yan and Cockcroft method, on the grounds that this test will if anything overestimate the chances of a difference between the Mortagy and the other two methods. Despite this, there was no difference in repeatability between the three techniques.
The repeatability of bronchial reactivity measurements depends on both subject and measurement factors-that is, the variability in the patients' nonspecific reactivity between tests and the consistency of the technique used to measure reactivity. By comparing the three methods in the same patients we are assuming that biological variability will be similar between the two measurements with each technique, so that the comparison of the three techniques is valid. These assumptions cannot, however, be made when we are comparing results from different groups of subjects. Subjects selected because their asthma is stable or who have previous experience of challenge testing would inevitably show better repeatability than less stable or less experienced asthmatic patients. This is likely to be the explanation for the less good repeatability for the Cockcroft method in our study than in some previous reports.8-12 For most of the subjects in our study this was the first experience of both spirometry and histamine challenge, and in this respect they are representative of subjects encountered in epidemiological studies.
The PC20 and PD20 values in our study show a similar relationship to symptoms of asthma to that seen in previous studies for all three methods-up to 20 mg/ml,'3 1 Mmol,3 and 0.5 mg/ml4 in asthmatic subjects with symptoms for the Cockcroft, Yan, and Mortagy methods respectively and up to 60 mg/ml13 and 5 pmol3 in symptom free asthmatics for the Cockcroft and Yan methods.
The failure to demonstrate a PC20 in all subjects with the Cockcroft technique is presumably due to a lower maximum inhaled dose of histamine. The total dose of histamine emitted from the nebuliser, 14.6 pmol, is delivered continuously during inspiration and expiration so most of it is lost to the atmosphere.
In contrast, the maximum doses of 7.8 and 7.3 umol with the Yan and Mortagy methods are delivered during inspiration only. These two methods were also completed in a shorter time, so a greater proportion of the cumulative histamine dose would be active at the end of the protocol.
Both the Yan and the Mortagy protocols were easy to perform, though the need to clean the nebuliser chamber between doses with the Mortagy method occupied most of the time available. A further disad- 
